| Patient trial population . | Tivozanib . | Sorafenib . | ||
|---|---|---|---|---|
| ITT N = 175 . | Prior-CPI N = 47 . | ITT N = 175 . | Prior-CPI N = 44 . | |
| Median PFS | 5.6 months | 7.3 months | 3.9 months | 5.1 months |
| PFS HR (95% CI), P-value | 0.73 (0.56, 0.95), P =.02 | 0.55 (0.32, 0.94) | ||
| Landmark 1-year PFS Rate | 28% | 37% | 11% | 5% |
| Median OS | 16.4 months | 18.1 months | 19.2 months | 20.9 months |
| OS HR (95% CI), P-value | HR = 0.89 (0.70, 1.14), P =.35 | HR = 0.69 (0.43, 1.11), P =.0992 | ||
| ORR % | 18% | 24% | 8% | 7% |
| Median DOR, months | 22.0 | 20.3 | 5.7 | 5.7 |
| Patient trial population . | Tivozanib . | Sorafenib . | ||
|---|---|---|---|---|
| ITT N = 175 . | Prior-CPI N = 47 . | ITT N = 175 . | Prior-CPI N = 44 . | |
| Median PFS | 5.6 months | 7.3 months | 3.9 months | 5.1 months |
| PFS HR (95% CI), P-value | 0.73 (0.56, 0.95), P =.02 | 0.55 (0.32, 0.94) | ||
| Landmark 1-year PFS Rate | 28% | 37% | 11% | 5% |
| Median OS | 16.4 months | 18.1 months | 19.2 months | 20.9 months |
| OS HR (95% CI), P-value | HR = 0.89 (0.70, 1.14), P =.35 | HR = 0.69 (0.43, 1.11), P =.0992 | ||
| ORR % | 18% | 24% | 8% | 7% |
| Median DOR, months | 22.0 | 20.3 | 5.7 | 5.7 |
Abbreviations: CPI, checkpoint inhibitor; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; TTR, time to treatment response; DOR, duration of response.
| Patient trial population . | Tivozanib . | Sorafenib . | ||
|---|---|---|---|---|
| ITT N = 175 . | Prior-CPI N = 47 . | ITT N = 175 . | Prior-CPI N = 44 . | |
| Median PFS | 5.6 months | 7.3 months | 3.9 months | 5.1 months |
| PFS HR (95% CI), P-value | 0.73 (0.56, 0.95), P =.02 | 0.55 (0.32, 0.94) | ||
| Landmark 1-year PFS Rate | 28% | 37% | 11% | 5% |
| Median OS | 16.4 months | 18.1 months | 19.2 months | 20.9 months |
| OS HR (95% CI), P-value | HR = 0.89 (0.70, 1.14), P =.35 | HR = 0.69 (0.43, 1.11), P =.0992 | ||
| ORR % | 18% | 24% | 8% | 7% |
| Median DOR, months | 22.0 | 20.3 | 5.7 | 5.7 |
| Patient trial population . | Tivozanib . | Sorafenib . | ||
|---|---|---|---|---|
| ITT N = 175 . | Prior-CPI N = 47 . | ITT N = 175 . | Prior-CPI N = 44 . | |
| Median PFS | 5.6 months | 7.3 months | 3.9 months | 5.1 months |
| PFS HR (95% CI), P-value | 0.73 (0.56, 0.95), P =.02 | 0.55 (0.32, 0.94) | ||
| Landmark 1-year PFS Rate | 28% | 37% | 11% | 5% |
| Median OS | 16.4 months | 18.1 months | 19.2 months | 20.9 months |
| OS HR (95% CI), P-value | HR = 0.89 (0.70, 1.14), P =.35 | HR = 0.69 (0.43, 1.11), P =.0992 | ||
| ORR % | 18% | 24% | 8% | 7% |
| Median DOR, months | 22.0 | 20.3 | 5.7 | 5.7 |
Abbreviations: CPI, checkpoint inhibitor; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; TTR, time to treatment response; DOR, duration of response.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
